SCHEMBL857177

SCHEMBL857177

CC1(C)CCc2nc(CCl)[nH]c(=O)c2C1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 3/20 0.38
▸ PARP1 P09874 2/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HTR2C P28335 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TNKS O95271 2/20 0.32
▸ SPR P35270 2/20 0.32
▸ PDK1 Q15118 1/20 0.32
▸ PARP15 Q460N3 1/20 0.31
▸ PARP3 Q9Y6F1 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ HPGD P15428 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17086607 0.74 HDAC6 (0.50) PARP1HDAC6HTR2CSPRHPGD
SCHEMBL6930694 0.74 HDAC6 (0.54) TNKS2PARP1HDAC6HTR2CSMN1; SMN2
SCHEMBL14603558 0.70 TNKS2 (0.54) TNKS2PARP1PARP2TNKS
SCHEMBL7776883 0.70 PARP1 (0.60) TNKS2PARP1PARP2HDAC6HTR2C
SCHEMBL14721437 0.67 TNKS2 (0.46) TNKS2PARP1PARP2TNKSSPR
SCHEMBL857347 0.67 PDK1 (0.33) TNKS2PARP1PARP2PDK1ACHE
SCHEMBL855822 0.66 PARP1 (0.41) TNKS2PARP1PARP2HTTSMN1; SMN2
SCHEMBL3236727 0.64 EEF2K (0.38) TNKS2PARP1PARP2PDK1ACHE
SCHEMBL18711692 0.63 SPR (0.48) PARP1HTTSPRPARP15PARP3
SCHEMBL856645 0.62 PDK1 (0.35) TNKS2PARP1PARP2PDK1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 — — US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 — — US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 — — US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 — — EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 — — WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 — — EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 — — US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA TNKS2 915/4885PARP1 2347/4885PARP2 2544/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA TNKS2 1525/4885PARP1 2511/4885PARP2 2928/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA TNKS2 917/4885PARP1 2250/4885PARP2 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback